Clinical Trial Update: Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating the safety of transitioning from selexipag to Remodulin and then to oral treprostinil in adults with pulmonary arterial hypertensi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Orenitram (treprostinil)
• Remodulin (treprostinil)
• Selexipag (selexipag)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: WITHDRAWN